Individual Patient Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.

• Screening Visit Week 0 The subject will go through a screening process that will last up to 14 days. During this time the Clinical Investigator will review labs and diagnostic test results to confirm study eligibility. Abnormal test results (i.e., ongoing infection), may require follow-up before proceeding with the treatment. This screening period will start with the "Screening Visit", which will include the following procedures:

1. Informed Consent will be obtained.

2. Demographics

3. Review of inclusion and exclusion criteria

4. Review of medical history and concomitant medications

5. Physical exam

6. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)

7. Height and weight

8. Blood samples will be collected for safety assessments:

9. Hematology

10. Chemistry

11. Coagulation Panel

12. A verification of patient consent will be verbally performed.

• Intervention 1 Day 1 (Week 1) and Intervention 2 Day 1 (Week 12) Once the eligibility is confirmed, +7 days after the screening visit, the subject will return to

HBSCRF to receive the IV treatment. Procedures will be assessed as follows:

1. Review of medical history, adverse events, and concomitant medications.
2. Physical exam
3. Patient pain assessment VAS of Pain
4. Patient pain assessment WOMAC Knee Score
5. Vital signs (Heart Rate, Blood Pressure, Respirations, Temp., SpO2)
6. Weight measurement
7. A verification of patient consent will be verbally performed
8. The HB-adMSCs will be administered and the patient closely observed: